AU2020319897A1 - FcRn antibodies and methods of use thereof - Google Patents

FcRn antibodies and methods of use thereof Download PDF

Info

Publication number
AU2020319897A1
AU2020319897A1 AU2020319897A AU2020319897A AU2020319897A1 AU 2020319897 A1 AU2020319897 A1 AU 2020319897A1 AU 2020319897 A AU2020319897 A AU 2020319897A AU 2020319897 A AU2020319897 A AU 2020319897A AU 2020319897 A1 AU2020319897 A1 AU 2020319897A1
Authority
AU
Australia
Prior art keywords
minutes
seq
sequence
less
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020319897A
Other languages
English (en)
Inventor
Santiago ARROYO
William Denney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of AU2020319897A1 publication Critical patent/AU2020319897A1/en
Assigned to MOMENTA PHARMACEUTICALS, INC. reassignment MOMENTA PHARMACEUTICALS, INC. Request for Assignment Assignors: JANSSEN BIOTECH, INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2020319897A 2019-08-01 2020-08-03 FcRn antibodies and methods of use thereof Pending AU2020319897A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881897P 2019-08-01 2019-08-01
US62/881,897 2019-08-01
PCT/US2020/044731 WO2021022249A1 (en) 2019-08-01 2020-08-03 Fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2020319897A1 true AU2020319897A1 (en) 2022-02-24

Family

ID=74229292

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020319897A Pending AU2020319897A1 (en) 2019-08-01 2020-08-03 FcRn antibodies and methods of use thereof

Country Status (8)

Country Link
US (1) US20220259308A1 (https=)
EP (1) EP4007605A4 (https=)
JP (2) JP2022542430A (https=)
CN (1) CN114630678A (https=)
AU (1) AU2020319897A1 (https=)
CA (1) CA3148826A1 (https=)
MX (1) MX2022001380A (https=)
WO (1) WO2021022249A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
AR131560A1 (es) * 2023-01-06 2025-04-09 argenx BV Métodos para tratar pots mediante el uso de antagonistas de fcrn
TW202527982A (zh) * 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
CN119326887B (zh) * 2024-10-20 2025-09-05 华中农业大学 动物FcRn蛋白在控制猪繁殖与呼吸综合征病毒感染性中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ251582A (en) * 1992-04-01 1997-07-27 Merck & Co Inc Recombinant human anti-hiv antibodies, methods for their cloning and expression and pharmaceutical compositions thereof
DK2236154T3 (en) * 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2009131702A2 (en) * 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
AU2011328246B2 (en) * 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
RS64768B1 (sr) * 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
CN109641045A (zh) * 2016-04-25 2019-04-16 Synt免疫公司 人源化亲和力成熟的抗fcrn抗体
SMT202400004T1 (it) * 2016-07-29 2024-03-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
BR112020006692A2 (pt) * 2017-10-04 2020-10-06 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para o tratamento de pacientes com glomerulonefrite membranoproliferativa
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CN113518783A (zh) * 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
JP2023509195A (ja) * 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
AU2021292200A1 (en) * 2020-06-17 2023-02-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients

Also Published As

Publication number Publication date
CA3148826A1 (en) 2021-02-04
JP2025138661A (ja) 2025-09-25
MX2022001380A (es) 2022-03-25
EP4007605A4 (en) 2023-08-16
CN114630678A (zh) 2022-06-14
US20220259308A1 (en) 2022-08-18
EP4007605A1 (en) 2022-06-08
WO2021022249A1 (en) 2021-02-04
JP2022542430A (ja) 2022-10-03

Similar Documents

Publication Publication Date Title
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
US20220259308A1 (en) Fcrn antibodies and methods of use thereof
US20230049725A1 (en) FcRn Antibodies and Methods of Use Thereof
US20220144946A1 (en) Fcrn antibodies and methods of use thereof
EP3723802A1 (en) Fcrn antibodies and methods of use thereof
EA050428B1 (ru) АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40072884A (en) Fcrn antibodies and methods of use thereof
CA2972822C (en) Fcrn antibodies and methods of use thereof
CN116782939A (zh) FcRn抗体及其使用方法
HK40104376A (en) Fcrn antibodies and methods of use thereof
HK40103769A (en) Fcrn antibodies and methods of use thereof
BR122021007991B1 (pt) Uso de anticorpos que se ligam a fcrn humana
BR112017015287B1 (pt) Anticorpos isolados que se ligam a fcrn humano, e composição farmacêutica

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MOMENTA PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): JANSSEN BIOTECH, INC.